Covid-19 could be vaccinated as early as the first half of next year if trials are a success, the Department for Business, Energy & Industrial Strategy (BEIS) said.
Human clinical studies of the vaccine will begin in September followed by a phase three study in December.Roger Connor, president of GSK Vaccines, said: “We believe that this adjuvanted vaccine candidate has the potential to play a significant role in overcoming the Covid-19 pandemic, both in the UK and around the world.“We thank the UK Government for confirmation of purchasing intent, which supports the significant investment we are already making as a company to scale up development and production of this vaccine.”Kate Bingham, chairwoman of the government’s Vaccines.